Summary Two P388 cell lines with acquired resistance to daunorubicin have been shown to exhibit crossresistance to anthrapyrazolone (NSC 357885). The degree of cross-resistance observed in these cell lines (58 and 150 fold) is similar to those observed towards daunorubicin (34 and 142 fold). However the decreased drug accumulation observed for daunorubicin in the resistant cell lines (4-6 fold) is not observed for anthrapyrazolone. Similarly, verapamil can increase daunorubicin accumulation in resistant cells but has no effect on anthrapyrazolone accumulation. It is concluded that in contrast to daunorubicin, decreased anthrapyrazolone accumulation is not the resistance mechanism operative in daunorubicin resistant cell lines towards anthrapyrazolone.
The anthrapyrazole class of intercalating agents has been shown to be effective against a variety of murine tumours (Showalter et al., 1984a) . These agents have been developed in an attempt to overcome the cardiotoxicity associated with the anthracycline antibiotics (Showalter et al., 1984b; Leopold et al., 1984) which is believed to arise due to free radical production following reduction of the anthracycline to a semiquinone radical. The anthra[1,9-cd] pyrazol-6(2H)-ones (anthrapyrazoles), in which the pyrazole ring is fused to the anthracene chromophore, are much less readily reduced compared with adriamycin. This may result in decreased free radical production.
In this study two P388 cell lines with acquired resistance to daunorubicin are shown to exhibit cross resistance to anthrapyrazolone. The decreased cellular retention of drug, observed in resistant cells on daunorubicin treatment, is not seen with anthrapyrazolone.
Materials and methods

Chemicals
Anthrapyrazolone (NSC 357885, PD 113785, CI-941) Flow cytofluorimetric determination of daunorubicin content was determined directly by flow cytometry as described previously (McGown et al., 1983) . Excitation was by the 488 nm line of an argon ion laser, and fluorescence emission monitored at 540 + 20 nm. This method was previously shown to be in good agreement with classical drug extraction procedures.
Results
It can be seen from the growth inhibition data (Table II) that the daunorubicin resistant cell lines show a high level of cross-resistance to anthrapyrazolone. The cellular accumulation of anthrapyrazolone in the parental (P388) and resistant (P388 R8/13) cell lines as a function of time is shown in Figure 1 . It can be seen that both cell lines incorporate the drug to the same level. Repetition of this experiment showed no statistical difference in anthrapyrazolone accumulation (Students t test) between these cell lines. Figure 1 Cellular accumulation of anthrapyrazolone in P388 (x) and P388 R8/13) (0) cell lines.
The effect of simultaneous incubation of verapamil (10 uM) on the uptake of either daunorubicin or anthrapyrazolone is shown in Table III . It can be seen that verapamil causes a considerable increase in the accumulation of daunorubicin in the resistant cell lines, but shows little (or no) effect on the parental P388 cell line. In contrast, verapamil addition has no comparable selective effect on anthrapyrazolone accumulation in the resistant cell lines. Following verapamil treatment, anthrapyrazolone incorporation is increased to a much lower extent than daunorubicin in the resistant cell lines. In contrast to daunorubicin, verapamil does not modify the relative uptake of anthrapyrazolone between the parental and resistant sublines. The small increase in anthrapyrazolone incorporation observed in these cell lines (10-20%) was however statistically significant (P<0.05, Students t test).
The effects of simultaneous incubation of anthrapyrazolone and daunorubicin on drug accumulation in the P388 and P388 R8/13 cell lines are shown in Figures 2 and 3 . The effect of increasing the concentration of anthrapyrazolone (0-20pM) in the presence of 10pM daunorubicin (Figure 2) shows no effect on daunorubicin accumulation in either the P388 or P388 R8/13 cell line. The effect of increasing concentrations of daunorubicin in the presence of anthrapyrazolone (1O0m) (Figure 3) shows a concentrationdependant increase in daunorubicin incorporation, with higher levels of daunorubicin taken up by the parental cell line. Little effect is seen on anthrapyrazolone accumulation in either cell line.
Similarly no increase in daunorubicin accumulation on coincubation with anthrapyrazolone was observed using a flow cytofluorimetric determination of intracellular daunorubicin concentration (Table IV) . The decrease in fluorescence observed on anthrapyrazolone incubation is due to the overlap of aborption spectra at the excition wavelength used in this study. Figure 3 Effect of increasing concentrations of daunorubicin in the presence of anthrapyrazolone (10 pm) on the cellular accumulation of both drugs. Curve 1, daunorubicin in P388 cells, curve 2, daunorubicin in P388 R8/13 cells, curve 3 anthrapyrazolone in P388 cells, and curve 4 anthrapyrazolone in P388 R8/13 cells. Exposure time was for 2h and the intracellular concentrations were measured by extraction procedures described in Materials and methods. processes (Showalter et al., 1984b; Leopold et al., 1984; Fry et al., 1984) . The phenomenon of cross-resistance between a wide variety of structurally diverse agents (e.g. the anthracyclines, vinca alkaloids, actinomycin D, mitoxantrone and menogarol) has already been widely reported (Tsuruo et al., 1985; Dano, 1972) . Resistance to these agents is associated with increased efflux of drug from cells (McGown et al., 1983; Dano et al., 1983) . The mechanism by which drug is excluded from resistant cells is not known but it has been shown to be energy dependant, and can be inhibited by some calcium channel blockers such as verapamil (Tsuruo et al., 1985; Dano et al., 1983) .
The novel agent anthrapyrazolone shows a high level of cross-resistance to two cell lines with acquired resistance to daunorubicin. The structural similarity of this agent to the anthracyclines, and the structural diversity found in the agents involved in the multi-drug resistance phenomenon (Tsuruo et al., 1985; Dano, 1972; McGown et al., 1983; Dano et al., 1983 ) makes this observed cross-resistance predictable. However the lack of differential accumulation of anthrapyrazolone between the parental and resistant cell lines is contrary to the expected result. The lack of any effect of verapamil in increasing the amount of anthrapyrazolone in the resistant cell lines is also evidence that drug efflux is not the important resistance mechanism towards this drug in our cell line. In the case of daunorubicin the drug level within the resistant cells can be increased to that observed in the parental cells. Further evidence against increased drug efflux as the mechanism of resistance towards anthrapyrazolone is shown in Figures 2 and 3 . It can be seen that the drug accumulation in the resistant cells is not affected by coincubation with combinatidns of daunorubicin and anthrapyrazolone, hence it is unlikely that these agents share the same drug efflux mechanism which is believed to be involved in pleotropic drug resistance.
These data suggest that resistance to anthrapyrazolone in these cell lines is not due to decreased drug retention. Resistance to daunorubicin is, however, associated with decreased drug retention. This leads to the conclusion that while decreased drug concentration within the cell may be a contributory factor to drug resistance other, perhaps more important processes, must also be operating within these resistant cells. This is in agreement with Capranico et al. (1986a, b) who have shown differential DNA damage in sensitive and doxorubicin-resistant P388 cell lines, which is independent of membrane changes. Klohs et al. (1986) showed, for a series of anthrapyrazolone derivatives (not including the one used in this study), that subtle changes in substitution on the anthrapyrazole moeity resulted in a large change in the degree of cross-resistance to an adriamycinresistant cell line. A number of calcium channel blockers and calmodulin antagonists including verapamil were shown to vary considerably in their effect on 72h growth inhibition in the presence of the anthracyclines and anthrapyrazolone derivatives. However no data was presented on the accumulation of the anthrapyrazole derivatives in the cell lines tested.
In conclusion, resistance to daunorubicin is associated with decreased intracellular drug levels, whereas the resistance mechanism operating towards anthrapyrazolone (NSC 357885) is not due to altered drug transport. The implications of this towards resistance to daunorubicin have yet to be elucidated.
